Systematic Financial Management LP Sells 65,642 Shares of AngioDynamics, Inc. $ANGO

Systematic Financial Management LP trimmed its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,504,864 shares of the medical instruments supplier’s stock after selling 65,642 shares during the period. Systematic Financial Management LP owned approximately 0.06% of AngioDynamics worth $32,162,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANGO. Goldman Sachs Group Inc. increased its stake in AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after acquiring an additional 22,658 shares during the period. Jane Street Group LLC increased its stake in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after acquiring an additional 34,054 shares during the period. Legal & General Group Plc increased its stake in AngioDynamics by 279.5% during the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares during the period. Rhumbline Advisers increased its stake in AngioDynamics by 4.3% during the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares during the period. Finally, American Century Companies Inc. increased its stake in AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after acquiring an additional 13,217 shares during the period. 89.43% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ANGO shares. Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.67.

AngioDynamics Trading Down 0.3%

ANGO stock opened at $11.92 on Friday. AngioDynamics, Inc. has a 1-year low of $8.36 and a 1-year high of $13.99. The firm has a market cap of $492.53 million, a P/E ratio of -15.89 and a beta of 0.37. The business’s 50 day moving average is $10.83 and its 200-day moving average is $11.42.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.19 EPS for the current year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.